Expertise in
2
conditions

Marcus K. Vetter

Cantonal Hospital Basel Land, 
Liestal, BL, CH 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
2
conditions
Cantonal Hospital Basel Land, 
Liestal, BL, CH 

Overview

Marcus Vetter practices practicing medicine in Liestal, Switzerland.

Mr. Vetter is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Cerebral Hypoxia, Endometrial Cancer, and Mastectomy.

He is actively involved in clinical research, co-authoring 75 peer reviewed articles and participating in 8 clinical trials.

Gender

Male

Locations

Cantonal Hospital Basel Land, Liestal, BL, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Circulating Tumor Cells (CTC) in Cancer
Circulating Tumor Cells (CTC) in Cancer
Enrollment Status: Recruiting
Publish Date: March 12, 2025
Intervention Type: Other
Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positive Early Breast Cancer
Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positive Early Breast Cancer
Enrollment Status: Completed
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drugs: Paclitaxel, Trastuzumab, Pertuzumab, Palbociclib, Letrozole
Study Phase: Phase 2
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2026
Intervention Type: Other
Study Phase: Not Applicable
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Enrollment Status: Approved_for_marketing
Publish Date: December 16, 2024
Intervention Type: Drug
Effect of Digoxin on Clusters of Circulating Tumor Cells (CTCs) in Breast Cancer Patients
Effect of Digoxin on Clusters of Circulating Tumor Cells (CTCs) in Breast Cancer Patients
Enrollment Status: Completed
Publish Date: December 13, 2023
Intervention Type: Drug
Study Drug: Digoxin
Study Phase: Early Phase 1
A 24 Weeks Activity Program in Patients With Early Breast Cancer Receiving Aromatase Inhibitor Therapy. A Multicenter Randomized Phase III Trial
A 24 Weeks Activity Program in Patients With Early Breast Cancer Receiving Aromatase Inhibitor Therapy. A Multicenter Randomized Phase III Trial
Enrollment Status: Completed
Publish Date: June 27, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
A Stratified, Multicenter Phase II Trial of Transdermal CR1447 (4-OH-testosterone) in Endocrine Responsive-HER2 Negative and Triple Negative-androgen Receptor Positive Metastatic or Locally Advanced Breast Cancer
A Stratified, Multicenter Phase II Trial of Transdermal CR1447 (4-OH-testosterone) in Endocrine Responsive-HER2 Negative and Triple Negative-androgen Receptor Positive Metastatic or Locally Advanced Breast Cancer
Enrollment Status: Terminated
Publish Date: June 27, 2023
Intervention Type: Drug
Study Drug: CR1447
Study Phase: Phase 2
View 7 Less Clinical Trials

75 Total Publications

Geriatric oncology: It's not just about age
Geriatric oncology: It's not just about age
Journal: MMW Fortschritte der Medizin
Published: August 07, 2026

Frequently Asked Questions about Marcus K. Vetter

Is Marcus K. Vetter a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Marcus K. Vetter is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Marcus K. Vetter participate in research or clinical trials?

Yes. Marcus K. Vetter has published 75 articles and abstracts on conditions like Breast Cancer. You can view a list of Marcus K. Vetter's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Vetter's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile